Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON50593
NL-OMON50593
Completed
Phase 3

A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. - POPular CABG

Sint Antonius Ziekenhuis0 sites499 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsbypass surgeryCoronary artery bypass grafting10011082

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
bypass surgery
Sponsor
Sint Antonius Ziekenhuis
Enrollment
499
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
December 31, 2020
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\) More than 21 years of age, 2\) Planned CABG with the use of 1 or more SVGs

Exclusion Criteria

  • •1\) Unable to give informed consent or a life expectancy of less than 1 year, 2\)
  • •Concomitant valve (excluding aortic bioprothesis), aorta or rhythm surgery
  • •during the same session, 3\) Inability to undergo CCTA, in the investigator\*s
  • •opinion, for instance due to severe claustrophobia or contrast allergy, 4\) Use
  • •of oral anticoagulants (acenocoumarol, fenprocoumon, NOACs) and a
  • •contraindication for discontinuation of this medication or the expectation that
  • •the patient will have an indication for the use of these drugs after surgery ,
  • •5\) Placement of a drug\-eluting stent in a coronary or cerebral artery within 6
  • •months of CABG or placement of a bare\-metal stent in a coronary or cerebral
  • •artery within 1 month of CABG , 6\) Use of other antiplatelet drugs than ASA

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A placebo-controlled, double-blind, randomized trial to evaluate the effect of 300 mg of inclisiran sodium given as subcutaneous injections in subjects with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C)hypercholesterolemia and elevated levels of cholesterol100822061000751010013317
NL-OMON48935The Medicines Company38
Completed
Phase 2
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients
NL-OMON46238Savara ApS9
Completed
Phase 2
A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysmAbdominal aortic aneurysmdilation of the aorta in the abdomen10002363
NL-OMON38947ovartis7
Completed
Phase 2
A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer*s DiseaseAlzheimer's diseasedementianeurodegenerative disease10012272
NL-OMON54863Cortexyme, Inc.31
Completed
Not Applicable
A randomized, double-blind, placebo-controlled study to investigate the effects of an 8-week recombinant human erythropoietin (NeoRecormon) treatment on well-trained cyclists and their cycling performance.FietsprestatieCycling performanceslow cycling
NL-OMON44014Centre for Human Drug Research48